Turmeric

Purported Benefits, Side Effects & More
Integrative Medicine
Developing Your Personal Care Plan
Integrative Medicine at Home Membership Program
Therapies, Classes & Workshops
About Herbs, Botanicals & Other Products
About Mind-Body Therapies
Our Research & Clinical Trials
Multimedia

Turmeric

Purported Benefits, Side Effects & More
Share
Share
Turmeric

Common Names

  • Indian saffron
  • Curcumin
  • Jiang huang

Jump to:

For Patients & Caregivers

Tell your healthcare providers about any dietary supplements you’re taking, such as herbs, vitamins, minerals, and natural or home remedies. This will help them manage your care and keep you safe.

What is it?

Turmeric is a plant that’s common in South Asia but is grown around the world. The underground part of the stem is a spice that has been used in cooking for hundreds of years. It is used in traditional medicine for many health issues.

Turmeric also comes as a dietary supplement in tablets, capsules and gummies.

The active substance in turmeric is curcumin. Curcumin is a powerful antioxidant. Antioxidants protect your cells from damage. Curcumin can also reduce swelling and pain.

What are the potential uses and benefits?

Turmeric is used to:

  • Reduce inflammation (swelling and redness)
  • Treat joint pain
  • Treat infections

Turmeric also has other uses that haven’t been studied by doctors to see if they work.

It’s generally safe to use turmeric in food and tea. Talk with your healthcare providers before taking supplements or higher amounts of turmeric. Herbal supplements are stronger than the herbs you would use in cooking.

Turmeric can also interact with some medications and affect how they work. For more information, read the “What else do I need to know?” section below.

What are the side effects?

Side effects of using turmeric may include:

  • Abdominal pain/discomfort
  • Skin rash
  • Hives
What else do I need to know?
  • Talk with your healthcare providers about using turmeric and foods that contain turmeric if you’re getting chemotherapy. In lab experiments, turmeric stopped some chemotherapy medications from working against breast cancer cells.
  • Talk with your healthcare providers about using turmeric and foods that contain turmeric if you have a family history of kidney stones. Taking turmeric supplements may put you at a higher risk of getting kidney stones.

Don’t take turmeric supplements if:

  • You’re taking aspirin, ibuprofen (Advil®, Motrin®), or Acetaminophen (Tylenol®). Turmeric may lessen the effects of these medications.
  • You’re taking indomethacin (Indocin®). Turmeric may lessen its effects.
  • You’re taking warfarin (Coumadin®) or other blood thinners. Turmeric may increase your risk of bleeding.
  • You’re taking chemotherapy medications such as camptothecin (Camptosar®), mechlorethamine (Mustargen®), doxorubicin (Adriamycin®, Rubex®), or cyclophosphamide (Cytoxan®, Neosar®). Turmeric may lessen the effects of these medications.
  • You’re taking tacrolimus (Prograf®). Curcumin supplements may increase side effects.
Back to top

For Healthcare Professionals

Scientific Name
Curcuma longa, Curcuma domestica
Clinical Summary

Prevalent in South Asia, turmeric is now cultivated in tropical areas around the world. Its rhizome is used as a spice in regional cuisines, and as a coloring agent in food and cosmetics. It is also used in traditional medicine systems for improving circulation and digestion. Turmeric extracts are marketed as dietary supplements to improve memory, for arthritis, and for cancer prevention. The active constituents are turmerone oil and water-soluble curcuminoids, among which curcumin has been the focus of research the past few years. Preclinical studies showed that it has weak phytoestrogenic activity, although at a concentration not achievable by oral ingestion (1), and exhibits neuroprotective (2), choleretic (3), anti-inflammatory (4), immunomodulatory (5), anti-proliferative (3), as well as chemopreventive properties (6) (7) (8). Curcumin, its analogs, and liposomal formulations also demonstrated chemosensitizing (9) (10) (11) and radiosensitizing effects (12) (13).

Clinical findings suggest benefits of turmeric for major depressive disorder  (62), and epidemiological data indicate improved cognitive performance in elderly Asians who consumed turmeric (14). But there were no benefits of curcumin supplements in patients with Alzheimer’s disease (15). Turmeric may also help alleviate symptoms associated with gastrointestinal issues  (81), irritable bowel syndrome  (16) and quiescent ulcerative colitis (17), as well as reduce arterial stiffness in patients with type 2 diabetes mellitus (77) and benefit children and adolescents with asthma (78). It was also found safe and as effective as paracetamol (82) or an NSAID (18) for treating osteoarthritis of the knee, but did not affect knee effusion-synovitis or cartilage composition (83). Topical use of turmeric reduced the size of lesions in patients with vitiligo (100).

Curcumin was also reported beneficial for osteoarthritis of knee (87) and sarcopenia in older subjects (84). In postmenopausal women, curcumin combined with aerobic exercise training improved vascular endothelial function (61). But findings of its effects on serum cholesterol levels are mixed (19) (20). A systematic review found that both turmeric and curcumin may benefit patients with non alcoholic fatty liver disease (75). When combined with antipsychotics, curcumin may also help control symptoms of chronic schizophrenia (79) and was associated with significant reductions in serum CRP and IL-6 (101) and triglyceride plasma levels (108) in hemodialysis patients.

In cancer settings, preliminary findings suggest benefits of turmeric supplements in improving quality of life and hematological parameters in breast cancer patients  (85) and in decreasing rates of hand-foot syndrome following capecitabine treatment (71).

In studies using curcumin, a phase II trial of patients with advanced pancreatic cancer reported clinically relevant biological activity in two patients despite limited absorption (22); a blend of green tea, pomegranate, broccoli and curcumin led to a reduction in the rate of prostate-specific antigen (PSA) increase among men with prostate cancer following a PSA relapse post-radical treatment (65); when given to colorectal cancer patients during the pre-surgery waiting period, curcumin improved cachexia (21) and anorexia-cachexia syndrome in patients with advanced head and neck cancer (106) but did not produce similar effects in patients with solid tumors (107); and when combined with hydroxytyrosol and omega-3 fatty acids, curcumin may help reduce inflammation and pain in early breast cancer patients with aromatase-induced musculoskeletal symptoms (80). But in patients with familial adenomatous polyposis, there was no reduction in lower intestinal tract adenomas with long-term use (70).

Additionally, mouthwashes containing curcumin (86) (109) were found beneficial against radiation-induced oral mucositis, and a curcumin lozenge affected improvements in patients with oral submucous fibrosis (88). Topical application of either curcumin or turmeric helped control oral mucositis (76) and radiotherapy-induced dermatitis (64) (102). Furthermore, curcumin may serve as a useful adjunct to cancer treatments: When combined with docetaxel (23) and gemcitabine (24) (25), it was found to be safe in early phase studies, but high doses were needed to achieve systemic effect (23) (25). In patients with metastatic colorectal cancer, curcumin was reported as a safe and tolerable adjunct to FOLFOX chemotherapy (72).

However, curcumin is known to interfere with cytochrome P450 enzymes (26) (27) and may interact with chemotherapy drugs like cyclophosphamide and doxorubicin (28). Overall, the development of turmeric for clinical use needs further investigation due to its inherent poor absorption, rapid metabolism, complex mechanistic profile, and largely preclinical data.

Food Sources

Turmeric is a major ingredient in curry powder, a spice mix commonly used in South Asian cuisine.

Purported Uses and Benefits
  • Inflammation
  • Arthritis
  • Infections
Mechanism of Action

The hepatoprotective effects of curcumin, the most researched active constituent in turmeric, may occur via MMP-13 induction and TGF-alpha inhibition (30), as well as anti-apoptotic/anti-necrotic mechanisms (31). However, it has also been shown to inhibit cell-cycle progression during normal liver regeneration (3).

A meta-analysis of randomized clinical trials revealed that curcumin is effective in decreasing the concentration of tumor necrosis factor-alpha, a key mediator in many inflammatory diseases (68). In vitro and animal studies of lung models point to antiproliferative and modulatory mechanisms involving inhibition of the signal transducer and activator of transcription 3 Stat3 pathway (32), matrix metalloproteinase, and vascular endothelial growth factor (33); caspase- and mitochondria-dependent apoptosis (34) (35); and cyclin-dependent kinase downregulation (35). Curcumin also appears to have synergistic effects with isoflavones, suppressing the prostate-specific antigen (PSA) production in prostate cells through anti-androgen effects (36).

Studies done on breast cancer show that curcumin may inhibit chemotherapy-induced apoptosis via inhibition of the c-Jun NH2-terminal kinase (JNK) pathway and generation of reactive oxygen species (ROS) (28). Data also suggest that curcumin induces apoptosis in human colon cancer cells independent of p21 expression (39). Curcumin’s antitumor actions appear to be due to its interactions with arachidonate metabolism and its in vivo antiangiogenic properties (14). Another possible chemopreventive mechanism may be via binding and activating the vitamin D receptor (VDR), thereby protecting the small intestine and colon where VDRs are expressed and vitamin D is known to serve an anticancer function (38). Curcumin also inhibited growth of uterine leiomyosarcoma cells by targeting the AKT-mTOR (RAC-alpha serine-threonine-protein kinase; mTOR (mammalian target of rapamycin) pathway (37). Curcumin may inhibit bladder cancer progression by downregulating the expression of beta-catenin, high levels of which are associated with several cancers (69).

Another study found that CRM1, an important nuclear exportin, is a cellular target of curcumin; and that the inhibition of nuclear traffic by curcumin may be responsible for its many biological effects (63).

Contraindications

Patients predisposed to kidney stone formation (50) should consult their physicians before using turmeric supplements.

Adverse Reactions

Possible gastrointestinal discomfort  (18)

Case Reports

  • Allergic dermatitis: Associated with the use of curcumin (52) (110).
  • Contact urticaria: Two cases, one of which was an occupational exposure, associated with use of curcumin powder (53).
  • Paclitaxel toxicity/Acute toxic hepatitis: In a 67-year-old lung cancer patient, related to a possible interaction with turmeric and contaminated chlorella which were taken during active cancer treatment (73). Although other supplements were also being used, increased paclitaxel plasma concentrations were attributed to potential CYP 2C9 and 3A4 inhibition of turmeric as among the causes.
  • Autoimmune Hepatitis: Three cases, one with a medical history of Hashimoto’s thyroiditis, associated with chronic consumption of turmeric. Symptoms resolved after discontinuing turmeric use in all cases (89) (90) (111).
  • Iron deficiency anemia: In a 66-year-old man, associated with use of high dose turmeric supplements. The condition resolved after stopping turmeric (91).
  • Neutropenia: In  a 51-year-old breast cancer patient following self medication with large amounts of turmeric root infusions while receiving chemotherapy. Her white blood cell counts returned to normal after stopping the turmeric regimen (92).
  • Hepatotoxicity/Liver injury: Associated with use of supplements with low dose curcumin (103) as well as those with increased bioavailability and high dosages of curcumin/curcuminoids. In all cases, symptoms resolved with cessation of turmeric use (93) (94) (95) (96) (97) (112) (113).
  • Fatality: Associated with intravenous administration of curcumin solution for the treatment of eczema in a 31-year-old woman. The cause of death was determined to be anoxic brain injury secondary to prolonged resuscitation following an adverse reaction to the curcumin solution (99).
  • Oxalate nephropathy: Associated with chronic turmeric supplementation in a 69-year-old man. His condition stabilized after discontinuing turmeric use (114).
Herb-Drug Interactions

Anticoagulants / Antiplatelets: Preclinical studies (54) (55) and a case report (66) suggest that turmeric can increase risk of bleeding.
Camptothecin: Turmeric inhibits camptothecin-induced apoptosis of breast cancer cell lines in vitro (28). Clinical relevance is not known.
Mechlorethamine: Turmeric inhibits mechlorethamine-induced apoptosis of breast cancer cell lines in vitro (28). Clinical relevance is not known.
Paclitaxel: A lung cancer patient suffered liver toxicity while undergoing active treatment with paclitaxel. Although he was taking multiple supplements, one of which was tainted, turmeric was thought to be among the likely causes (73). But in a study of 60 breast cancer patients on treatment with paclitaxel, concurrent administration of 2 g/day turmeric produced only small changes in pharmacokinetic parameters that were deemed clinically irrelevant (104).
Doxorubicin: Turmeric inhibits doxorubicin-induced apoptosis of breast cancer cell lines in vitro (28). Clinical relevance is not known.
Cyclophosphamide: Dietary turmeric inhibits cyclophosphamide-induced tumor regression in animal studies (28). Clinical relevance is not known.
Norfloxacin: Pretreatment with curcumin resulted in increased plasma elimination half-life, thereby reducing the dosage of norfloxacin in animal model (56). Clinical relevance is not known.
Amphotericin B: Curcumin enhanced the effect, and decreased the toxicity of amphotericin B, in vitro (57). Clinical relevance is not known.
Drugs metabolized by the CYP3A4 enzyme: Curcumin inhibits cytochrome 3A4 enzyme, altering the metabolism of some prescription drugs (26). But according to conflicting data, short-term use of curcumin did not result in a clinically relevant interaction in healthy volunteers (67).
Drugs metabolized by the CYP1A2 enzyme: Curcumin inhibits cytochrome 1A2 enzyme, affecting the metabolism of certain prescription medicines, in vitro. Clinical relevance is not known (27).
Drugs metabolized by the CYP2A6 enzyme: Curcumin enhances cytochrome 2A6 enzyme, and can affect the metabolism of certain prescription drugs (27). Clinical relevance is not known.
Drugs metabolized by the CYP2D6 enzyme: Curcumin inhibits cytochrome 2D6 activity and has the potential to interact with CYP2D6 substrates (74). Clinical relevance is not known.
Celiprolol and Midazolam: Curcumin was shown to downregulate intestinal P-gp levels, thereby increasing the concentrations of celiprolol and midazolam in a murine model (48). Clinical relevance is not known.
Verapamil: Curcumin inhibited intestinal P-gp expression and function, thereby increasing concentrations of verapamil, in vitro (47). Clinical relevance is not known.
Tacrolimus: Pretreatment with turmeric increased the plasma levels of tacrolimus in a murine model (59). Acute calcineurin inhibitor nephrotoxicity was reported in a patient with a history of orthotopic liver transplantation following concurrent use of high amounts of turmeric  (98). 
Acetaminophen: The cytotoxic effects of curcumin increased significantly in the presence of acetaminophen in vitro (60). Clinical relevance is not known.
Ibuprofen: The cytotoxic effects of curcumin increased significantly in the presence of ibuprofen (60). Clinical relevance is not known.
Aspirin: The cytotoxic effects of curcumin increased significantly in the presence of aspirin (60). Clinical relevance is not known.
Losartan: Curcumin potentiated the blood pressure-lowering effects of losartan in hypertensive rats (105). Clinical significance is yet undetermined.

Herb Lab Interactions

Curcumin can interfere with thioflavin T assays due to its strong absorptive and fluorescent properties (58).

Dosage (OneMSK Only)
References
  1. Bachmeier BE, Mirisola V, Romeo F, et al. Reference profile correlation reveals estrogen-like trancriptional activity of Curcumin. Cell Physiol Biochem. 2010;26(3):471-482.
  2. Cemil B, Topuz K, Demircan MN, et al. Curcumin improves early functional results after experimental spinal cord injury. Acta Neurochir (Wien). Sep 2010;152(9):1583-1590; discussion 1590.
  3. Seehofer D, Schirmeier A, Bengmark S, et al. Inhibitory effect of curcumin on early liver regeneration following partial hepatectomy in rats. J Surg Res. Aug 2009;155(2):195-200.
  4. Yun JM, Jialal I, Devaraj S. Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem. May 2011;22(5):450-458.
  5. Jantan I, Bukhari SN, Lajis NH, et al. Effects of diarylpentanoid analogues of curcumin on chemiluminescence and chemotactic activities of phagocytes. J Pharm Pharmacol. Mar 2012;64(3):404-412.
  6. Chang KW, Hung PS, Lin IY, et al. Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBPalpha during oral cancer suppression. Int J Cancer. Jul 1 2010;127(1):9-20.
  7. Siwak DR, Shishodia S, Aggarwal BB, et al. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer. Aug 15 2005;104(4):879-890.
  8. Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene. Oct 27 2005;24(47):7022-7030.
  9. Kunnumakkara AB, Guha S, Krishnan S, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. Apr 15 2007;67(8):3853-3861.
  10. Selvendiran K, Ahmed S, Dayton A, et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther. Nov 1 2011;12(9):837-845.
  11. Sreekanth CN, Bava SV, Sreekumar E, et al. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene. Jul 14 2011;30(28):3139-3152.
  12. Qiao Q, Jiang Y, Li G. Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-kappaB pathway: an in-vitro study of lymphoma. Anticancer Drugs. Jan 23 2012.
  13. Kunnumakkara AB, Diagaradjane P, Guha S, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. Apr 1 2008;14(7):2128-2136.
  14. Ng TP, Chiam PC, Lee T, et al. Curry consumption and cognitive function in the elderly. Am J Epidemiol. Nov 1 2006;164(9):898-906.
  15. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. Feb 2008;28(1):110-113.
  16. Bundy R, Walker AF, Middleton RW, et al. Turmeric extract may improve irritable bowel syndrome symptomatology in otherwise healthy adults: a pilot study. J Altern Complement Med. Dec 2004;10(6):1015-1018.
  17. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical Gastroenterol Hepatol. Dec 2006;4(12):1502-1506.
  18. Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014 Mar 20;9:451-8.
  19. Pungcharoenkul K, Thongnopnua P. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res. Nov 2011;25(11):1721-1726.
  20. Baum L, Cheung SK, Mok VC, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. Dec 2007;56(6):509-514.
  21. He ZY, Shi CB, Wen H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. Mar 2011;29(3):208-213.
  22. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. Jul 15 2008;14(14):4491-4499.
  23. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. Jan 2010;9(1):8-14.
  24. Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. Jul 2011;68(1):157-164.
  25. Epelbaum R, Schaffer M, Vizel B, et al. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010;62(8):1137-1141.
  26. Zhang W, Lim LY. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos. Jul 2008;36(7):1283-1290.
  27. Chen Y, Liu WH, Chen BL, et al. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. Ann Pharmacother. Jun 2010;44(6):1038-1045.
  28. Somasundaram S, Edmund NA, Moore DT, et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. Jul 1 2002;62(13):3868-3875.
  29. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons; 1996.
  30. Morsy MA, Abdalla AM, Mahmoud AM, et al. Protective effects of curcumin, alpha-lipoic acid, and N-acetylcysteine against carbon tetrachloride-induced liver fibrosis in rats. J Physiol Biochem. Oct 11 2011.
  31. Bulku E, Stohs SJ, Cicero L, et al. Curcumin exposure modulates multiple pro-apoptotic and anti-apoptotic signaling pathways to antagonize acetaminophen-induced toxicity. Curr Neurovasc Res. Feb 1 2012;9(1):58-71.
  32. Alexandrow MG, Song LJ, Altiok S, et al. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. Dec 7 2011.
  33. Lin SS, Lai KC, Hsu SC, et al. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett. Nov 28 2009;285(2):127-133.
  34. Chen QY, Lu GH, Wu YQ, et al. Curcumin induces mitochondria pathway mediated cell apoptosis in A549 lung adenocarcinoma cells. Oncol Rep. May 2010;23(5):1285-1292.
  35. Wu SH, Hang LW, Yang JS, et al. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res. Jun 2010;30(6):2125-2133.
  36. Ide H, Tokiwa S, Sakamaki K, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate. Jul 1 2010;70(10):1127-1133.
  37. Wong TF, Takeda T, Li B, et al. Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition. Gynecol Oncol. Jul 2011;122(1):141-148.
  38. Bartik L, Whitfield GK, Kaczmarska M, et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem. Dec 2010;21(12):1153-1161.
  39. Watson JL, Hill R, Lee PW, et al. Curcumin induces apoptosis in HCT-116 human colon cancer cells in a p21-independent manner. Exp Mol Pathol. Jun 2008;84(3):230-233.
  40. Yang KY, Lin LC, Tseng TY, et al. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. Jun 15 2007;853(1-2):183-189.
  41. Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. Jan 2005;14(1):120-125.
  42. Bishnoi M, Chopra K, Rongzhu L, et al. Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence. Neurotox Res. Oct 2011;20(3):215-225.
  43. Tsai YM, Chien CF, Lin LC, et al. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm. Sep 15 2011;416(1):331-338.
  44. Orr WS, Denbo JW, Saab KR, et al. Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition. Surgery. Jan 26 2012.
  45. Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci. Oct 27 2000;67(23):2785-2793.
  46. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology. 1980;16(3):259-265.
  47. Hou XL, Takahashi K, Tanaka K, et al. Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int J Pharm. Jun 24 2008;358(1-2):224-229.
  48. Zhang W, Tan TM, Lim LY. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos. Jan 2007;35(1):110-115.
  49. Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, et al. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology. Jun 3 2007;235(1-2):83-91.
  50. Tang M, Larson-Meyer DE, Liebman M. Effect of cinnamon and turmeric on urinary oxalate excretion, plasma lipids, and plasma glucose in healthy subjects. Am J Clin Nutr. May 2008;87(5):1262-1267.
  51. Ulbricht CE, Basch, EM. Natual Standard Herb & Supplement Reference: Evidence-Based Clinical Reviews St. Louis, MO: Elsevier Mosby; 2005.
  52. Lamb SR, Wilkinson SM. Contact allergy to tetrahydrocurcumin. Contact Dermatitis. Apr 2003;48(4):227.
  53. Liddle M, Hull C, Liu C, et al. Contact urticaria from curcumin. Dermatitis. Dec 2006;17(4):196-197.
  54. Prakash P, Misra A, Surin WR, et al. Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb Res. Feb 2011;127(2):111-118.
  55. Jantan I, Raweh SM, Sirat HM, et al. Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation. Phytomedicine. Apr 2008;15(4):306-309.
  56. Pavithra BH, Prakash N, Jayakumar K. Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. J Vet Sci. Dec 2009;10(4):293-297.
  57. Kudva AK, Manoj, MN, Swamy, BM, et al. Complexation of amphotericin B and curcumin with serum albumins: solubility and effect on erythrocyte membrane damage. J Exp Pharmacol. 2011;2011(3):1-6.
  58. Hudson SA, Ecroyd H, Kee TW, et al. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J. Oct 2009;276(20):5960-5972.
  59. Egashira K, Sasaki H, Higuchi S, Ieiri I. Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats. Drug Metab Pharmacokinet. 2012 Apr 25;27(2):242-7.
  60. Choi HA, Kim MR, Park KA, Hong J. Interaction of over-the-counter drugs with curcumin: influence on stability and bioactivities in intestinal cells. J Agric Food Chem. 2012 Oct 24;60(42):10578-84.
  61. Akazawa N, Choi Y, Miyaki A, et al. Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutr Res. 2012 Oct;32(10):795-9.
  62. Sanmukhani J, Satodia V, Trivedi J, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014 Apr;28(4):579-85.
  63. Niu M, Wu S, Mao L, Yang Y. CRM1 is a cellular target of curcumin: new insights for the myriad of biological effects of an ancient spice. Traffic. 2013 Oct;14(10):1042-52.
  64. Palatty PL, Azmidah A, Rao S, et al. Topical application of a sandal wood oil and turmeric based cream prevents radiodermatitis in head and neck cancer patients undergoing external beam radiotherapy: a pilot study. Br J Radiol. 2014 Jun;87(1038):20130490.
  65. Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis. 2014 Jun;17(2):180-6.
  66. Daveluy A, Geniaux H, Thibaud L, et al. Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa). Therapie. Nov-Dec 2014;69(6):519-520.
  67. Volak LP, Hanley MJ, Masse G, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013 Feb;75(2):450-62.
  68. Sahebkar A, Cicero AF, Simental-Mendía LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res. 2016 May;107:234-42.
  69. Shi J, Wang Y, Jia Z et al. Curcumin inhibits bladder cancer progression via regulation of β-catenin expression. Tumour Biol. 2017 Jul;39(7):1010428317702548.
  70. Cruz-Correa M, Hylind LM, Marrero JH, et al. Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology. Sep 2018;155(3):668-673.
  71. Scontre VA, Martins JC, de Melo Sette CV, et al. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study. J Diet Suppl. Sep 3 2018;15(5):606-612.
  72. Howells LM, Iwuji COO, Irving GRB, et al. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. J Nutr. 2019 Jul 1;149(7):1133-1139.
  73. Costa ML, Rodrigues JA, Azevedo J, et al. Hepatotoxicity induced by paclitaxel interaction with turmeric in association with a microcystin from a contaminated dietary supplement. Toxicon. Aug 2018;150:207-211.
  74. Al-Jenoobi FI, Al-Thukair AA, Alam MA, et al. Effect of Curcuma longa on CYP2D6- and CYP3A4-mediated metabolism of dextromethorphan in human liver microsomes and healthy human subjects. Eur J Drug Metab Pharmacokinet. Mar 2015;40(1):61-66.
  75. Goodarzi R, Sabzian K, Shishehbor F, Mansoori A. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2019 Mar;33(3):561-570.
  76. Normando AGC, de Menêses AG, de Toledo IP, et al. Effects of turmeric and curcumin on oral mucositis: A systematic review. Phytother Res. 2019 Mar 6. doi: 10.1002/ptr.6326. [Epub ahead of print]
  77. Srinivasan A, Selvarajan S, Kamalanathan S, Kadhiravan T, Prasanna Lakshmi NC, Adithan S. Effect of Curcuma longa on vascular function in native Tamilians with type 2 diabetes mellitus: A randomized, double-blind, parallel arm, placebo-controlled trial. Phytother Res. 2019 Jul;33(7):1898-1911.
  78. Manarin G, Anderson D, Silva JME, Coppede JDS, Roxo-Junior P, Pereira AMS, Carmona F. Curcuma longa L. ameliorates asthma control in children and adolescents: A randomized, double-blind, controlled trial. J Ethnopharmacol. 2019 Jun 28;238:111882.
  79. Miodownik C, Lerner V, Kudkaeva N, et al. Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. Clin Neuropharmacol. 2019 Jul/Aug;42(4):117-122.
  80. Martínez N, Herrera M, Frías L, et al. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. Clin Transl Oncol. 2019 Apr;21(4):489-498.
  81. Lopresti AL, Smith SJ, Rea A, Michel S. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study. BMC Complement Med Ther. 2021 Jan 21;21(1):40.
  82. Singhal S, Hasan N, Nirmal K, et al. Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol. Trials. 2021 Jan 30;22(1):105.
  83. Wang Z, Jones G, Winzenberg T, et al. Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis : A Randomized Trial. Ann Intern Med. 2020 Dec 1;173(11):861-869.
  84. Varma K, Amalraj A, Divya C, Gopi S. The Efficacy of the Novel Bioavailable Curcumin (Cureit) in the Management of Sarcopenia in Healthy Elderly Subjects: A Randomized, Placebo-Controlled, Double-Blind Clinical Study. J Med Food. 2021 Jan;24(1):40-49.
  85. Kalluru H, Kondaveeti SS, Telapolu S, Kalachaveedu M. Turmeric supplementation improves the quality of life and hematological parameters in breast cancer patients on paclitaxel chemotherapy: A case series. Complement Ther Clin Pract. 2020 Nov;41:101247.
  86. Shah S, Rath H, Sharma G, Senapati SN, Mishra E. Effectiveness of curcumin mouthwash on radiation-induced oral mucositis among head and neck cancer patients: A triple-blind, pilot randomised controlled trial. Indian J Dent Res. 2020 Sep-Oct;31(5):718-727.
  87. Lopresti AL, Smith SJ, Jackson-Michel S, Fairchild T. An Investigation into the Effects of a Curcumin Extract (Curcugen®) on Osteoarthritis Pain of the Knee: A Randomised, Double-Blind, Placebo-Controlled Study. Nutrients. 2021 Dec 23;14(1):41.
  88. Srivastava R, Kundu A, Pradhan D, Jyoti B, Chokotiya H, Parashar P. A Comparative Study to Evaluate the Efficacy of Curcumin Lozenges (TurmNova®) and Intralesional Corticosteroids with Hyaluronidase in Management of Oral Submucous Fibrosis. J Contemp Dent Pract. 2021 Jul 1;22(7):751-755.
  89. Lukefahr AL, McEvoy S, Alfafara C, Funk JL. Drug-induced autoimmune hepatitis associated with turmeric dietary supplement use. BMJ Case Rep. 2018 Sep 10;2018:bcr2018224611.
  90. Lee BS, Bhatia T, Chaya CT, Wen R, Taira MT, Lim BS. Autoimmune Hepatitis Associated With Turmeric Consumption ACG Case Rep J. 2020 Mar 16;7(3):e00320.
  91. Smith TJ, Ashar BH. Iron Deficiency Anemia Due to High-dose Turmeric. Cureus. 2019 Jan 9;11(1):e3858.
  92. Abdel-Razeq R, Iweir S, Awabdeh T, Barakat F, Abdel-Razeq H. Prolonged Neutropenia and Yellowish Discoloration of the Skin, But Not the Sclera, Following Excessive Turmeric Raw Root Ingestion. Cureus. 2021 Apr 29;13(4):e14754.
  93. Luber RP, Rentsch C, Lontos S, et al. Turmeric Induced Liver Injury: A Report of Two Cases. Case Reports Hepatol. 2019 Apr 28;2019:6741213.
  94. Chand S, Hair C, Beswick L. A rare case of turmeric-induced hepatotoxicity. Intern Med J. 2020 Feb;50(2):258-259.
  95. Suhail FK, Masood U, Sharma A, John S, Dhamoon A. Turmeric supplement induced hepatotoxicity: a rare complication of a poorly regulated substance. Clin Toxicol (Phila). 2020 Mar;58(3):216-217.
  96. Lombardi N, Crescioli G, Maggini V, et al. Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports. Br J Clin Pharmacol. 2021 Mar;87(3):741-753.
  97. Sohal A, Alhankawi D, Sandhu S, Chintanaboina J. Turmeric-Induced Hepatotoxicity: Report of 2 Cases. Int Med Case Rep J. 2021 Dec 22;14:849-852.
  98. Nayeri A, Wu S, Adams E, et al. Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report. Transplant Proc. 2017 Jan-Feb;49(1):198-200.
  99. Lasoff DR, Cantrell FL, Ly BT. Death associated with intravenous turmeric (Curcumin) preparation. Clin Toxicol (Phila). 2018 May;56(5):384-385.
  100. Jalalmanesh S, Mansouri P, Rajabi M, Monji F. Therapeutic effects of turmeric topical cream in vitiligo: A randomized, double-blind, placebo-controlled pilot study. J Cosmet Dermatol. 2022 Oct;21(10):4454-4461.
  101. Arabi SM, Bahari H, Hamidipor S, et al. The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: A systematic review and meta-analysis. Phytother Res. 2022 Dec;36(12):4361-4370.
  102. Ostadi A, Arab-Zozani M, Zarei E, Ferns GA, Bahrami A. Therapeutic effect of turmeric on radiodermatitis: A systematic review. Physiol Rep. 2023 Mar;11(5):e15624.
  103. Sunagawa SW, Houlihan C, Reynolds B, et al. Turmeric-Associated Drug-Induced Liver Injury. ACG Case Rep J. 2022 Dec 26;9(12):e00941.
  104. Kalluru H, Mallayasamy SR, Kondaveeti SS, et al. Effect of turmeric supplementation on the pharmacokinetics of paclitaxel in breast cancer patients: A study with population pharmacokinetics approach. Phytother Res. 2022 Apr;36(4):1761-1769.
  105. Ahad A, Raish M, Abdelrahman IA, et al. Changes in Pharmacokinetics and Pharmacodynamics of Losartan in Experimental Diseased Rats Treated with Curcuma longa and Lepidium sativum. Pharmaceuticals (Basel). 2022 Dec 26;16(1):33.
  106. Thambamroong T, Seetalarom K, Saichaemchan S, Pumsutas Y, Prasongsook N. Efficacy of Curcumin on Treating Cancer Anorexia-Cachexia Syndrome in Locally or Advanced Head and Neck Cancer: A Double-Blind, Placebo-Controlled Randomised Phase IIa Trial (CurChexia). J Nutr Metab. 2022 Jun 2;2022:5425619.
  107. Chaiworramukkul A, Seetalarom K, Saichamchan S, Prasongsook N. A Double-Blind, Placebo-Controlled Randomized Phase IIa Study: Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Solid Cancer Patients. Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2333-2340.
  108. Alvarenga L, Cardozo LFMF, Ribeiro-Alves M, et al. Effects of turmeric extract supplementation on the lipid and lipoprotein subfraction profile in hemodialysis patients: A randomised, double-blind, crossover and controlled trial.  Phytother Res. 2023 Aug;37(8):3424-3437.
  109. Martins AFL, Pereira CH, Morais MO, et al. Effects of a mucoadhesive phytomedicine (Curcuma longa L. and Bidens pilosa L.) on radiotherapy-induced oral mucositis and quality of life of patients undergoing head and neck cancer treatment: randomized clinical trial.  Support Care Cancer. 2023 Aug 11;31(9):517.
  110. Babu D, Rai R. Allergic and photoaggravated contact dermatitis from turmeric in mangalsutra: A cultural dermatosis. Contact Dermatitis. 2023 Nov;89(5):396-397.
  111. Arzallus T, Izagirre A, Castiella A, Torrente S, Garmendia M, Zapata EM. Drug induced autoimmune hepatitis after turmeric intake.  Gastroenterol Hepatol. 2023 Dec;46(10):805-806. 
  112. Haloub K, McNamara E, Yahya RH. An Unusual Case of Dietary-Induced Liver Injury during Pregnancy: A Case Report of Probable Liver Injury due to High-Dose Turmeric Intake and Literature Review. Case Reports Hepatol. 2024 Feb 6;2024:6677960. 
  113. Smith DN, Pungwe P, Comer LL, Ajayi TA, Suarez MG. Turmeric-Associated Liver Injury: A Rare Case of Drug-Induced Liver Injury. Cureus. 2023 Mar 31;15(3):e36978.
  114. Washington O, Robinson E, Simh D, et al. Oxalate nephropathy and chronic turmeric supplementation: a case report. J Bras Nefrol. 2024 Jan-Mar;46(1):99-106. 
Back to top
Back to top
Email your questions and comments to [email protected].

Last Updated